Dechert Advises Aquestive Therapeutics on Two Transactions to Assist in Launch of Anaphylm Sublingual Film
Dechert represented Aquestive Therapeutics Inc. in two transactions aimed at advancing the launch and commercialization of Anaphylm Sublingual Film, a polymer matrix-based epinephrine prodrug designed as a rescue treatment for severe allergic reactions including anaphylaxis.